591 related articles for article (PubMed ID: 9816095)
21. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
Itoh T; Storkus WJ; Gorelik E; Lotze MT
J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
[TBL] [Abstract][Full Text] [Related]
22. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
Robbins PF; el-Gamil M; Li YF; Topalian SL; Rivoltini L; Sakaguchi K; Appella E; Kawakami Y; Rosenberg SA
J Immunol; 1995 Jun; 154(11):5944-50. PubMed ID: 7751637
[TBL] [Abstract][Full Text] [Related]
23. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
25. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
[TBL] [Abstract][Full Text] [Related]
26. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Kang X; Kawakami Y; el-Gamil M; Wang R; Sakaguchi K; Yannelli JR; Appella E; Rosenberg SA; Robbins PF
J Immunol; 1995 Aug; 155(3):1343-8. PubMed ID: 7543520
[TBL] [Abstract][Full Text] [Related]
27. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
van der Bruggen P; Szikora JP; Boël P; Wildmann C; Somville M; Sensi M; Boon T
Eur J Immunol; 1994 Sep; 24(9):2134-40. PubMed ID: 7522162
[TBL] [Abstract][Full Text] [Related]
28. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
[TBL] [Abstract][Full Text] [Related]
29. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
30. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
31. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
[TBL] [Abstract][Full Text] [Related]
32. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
Stötter H; Wiebke EA; Tomita S; Belldegrun A; Topalian S; Rosenberg SA; Lotze MT
J Immunol; 1989 Mar; 142(5):1767-73. PubMed ID: 2493053
[TBL] [Abstract][Full Text] [Related]
33. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
34. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
36. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
Crowley NJ; Slingluff CL; Darrow TL; Seigler HF
Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572
[TBL] [Abstract][Full Text] [Related]
37. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.
Hom SS; Schwartzentruber DJ; Rosenberg SA; Topalian SL
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):18-30. PubMed ID: 8435428
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
39. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
40. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
